润都股份: 关于氢氯噻嗪获得化学原料药上市申请批准通知书的公告

Group 1 - The company, Zhuhai Runduo Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the listing application of hydrochlorothiazide as a chemical raw material drug [1] - The approval enhances the company's product portfolio and improves its competitiveness in the market, which is expected to have a positive impact on future operating performance [1] - The drug is indicated for conditions such as edema, hypertension, central or renal diabetes insipidus, and kidney stones [1] Group 2 - The approval process included a supplementary research notification received in January 2025, with the company completing the required work and submitting documentation by May 2025, leading to the final approval in August 2025 [1] - The registration number for the drug is Y20240000290, and the notification number is 2025YS00718 [1]